Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Regeneron Pharmaceuticals Inc's Business Segments
Regeneron Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
9
Largest Segment
Collaboration Revenue
Total Revenue
$ 4,291
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Collaboration Revenue44.3%
- Product35.8%
- Share of Profit (Losses)33.8%
- Libtayo Net Product Sales10.2%
- Product and Service, Other4%
- Reimbursement for Manufacturing of Commercial Supplies3.6%
- Other Products0.7%
- Lynozyfic0.3%
- Non-US0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenue | $ 1,900 | 44.3% |
| Product | $ 1,535 | 35.8% |
| Share of Profit (Losses) | $ 1,451 | 33.8% |
6 more segments available
Sign in to unlock the full Regeneron Pharmaceuticals Inc dataset.
Revenue by Product & Service Category - FY
- Collaboration Revenue52.7%
- Product42.6%
- Share of Profit (Losses)40.2%
- Eylea HD and Eylea26.1%
- Eylea Net Product Sales13.1%
- Eylea HD13%
- Libtayo Net Product Sales7.9%
- Product and Service, Other4.7%
- Reimbursement for Manufacturing of Commercial Supplies4.3%
- Praluent Net Product Sales1.8%
- Evkeeza1.3%
- Other Products0.9%
- Lynozyfic0.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenue | $ 1,900 | 52.7% |
| Product | $ 1,535 | 42.6% |
| Share of Profit (Losses) | $ 1,451 | 40.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
10 more categories available
Sign in to unlock the full Regeneron Pharmaceuticals Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Collaboration Revenue44.3%
- Product35.8%
- Share of Profit (Losses)33.8%
- Libtayo Net Product Sales10.2%
- Product and Service, Other4%
- Reimbursement for Manufacturing of Commercial Supplies3.6%
- Other Products0.7%
- Lynozyfic0.3%
- Non-US0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenue | $ 1,900 | 44.3% |
| Product | $ 1,535 | 35.8% |
| Share of Profit (Losses) | $ 1,451 | 33.8% |
6 more segments available
Sign in to unlock the full Regeneron Pharmaceuticals Inc dataset.
Description of Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc. is a leading biotechnology company recognized for its commitment to developing and commercializing innovative therapies for serious medical conditions. Founded in 1988 and headquartered in Tarrytown, New York, the company has experienced substantial growth and has established itself as one of the premier biotech firms globally.
With a vast footprint that includes a 579-acre research and development campus, Regeneron is home to over 8,000 employees, encompassing a diverse team of scientists, researchers, and clinicians. These professionals collaborate to advance medical research and bring forth groundbreaking medicines that address some of the most pressing healthcare challenges.
Regenerons product portfolio features a range of biologics—therapeutics derived from living organisms—that target various serious conditions, including age-related macular degeneration (AMD), diabetic macular edema, atopic dermatitis, asthma, and certain types of cancer. The companys focus on biologics, combined with its proprietary technology platforms, has led to the development of highly effective treatments that have significantly improved patient outcomes.
Among its flagship products, Eylea stands out as a transformative treatment for AMD, a condition that can lead to vision loss in older adults. Eylea has become a cornerstone in the management of retinal diseases. Another key product, Dupixent, is indicated for moderate-to-severe atopic dermatitis and has been a game changer for patients suffering from chronic skin conditions.
In addition to its established products, Regeneron has played a crucial role in addressing the COVID-19 pandemic. The company developed REGEN-COV, a monoclonal antibody cocktail that has demonstrated efficacy in reducing hospitalization and mortality among COVID-19 patients. This rapid response showcases Regenerons agility and commitment to public health needs, leading to regulatory approvals and widespread use across multiple regions.
Regeneron emphasizes a robust pipeline of candidates in various stages of research and clinical trials, exploring treatments for an array of diseases, including autoimmune conditions, cancers, and rare genetic disorders. The company’s extensive investment in research and development, along with strategic collaborations, furthers its mission to discover and deliver groundbreaking therapies.
In summary, Regeneron Pharmaceuticals Inc. stands as a beacon of innovation within the biotechnology landscape, dedicated to tackling serious medical issues through advanced research and leading-edge therapeutic solutions. Its continued effort to enhance patient care and its commitment to scientific excellence position it as a key player poised for sustained success in the biotech industry.
With a vast footprint that includes a 579-acre research and development campus, Regeneron is home to over 8,000 employees, encompassing a diverse team of scientists, researchers, and clinicians. These professionals collaborate to advance medical research and bring forth groundbreaking medicines that address some of the most pressing healthcare challenges.
Regenerons product portfolio features a range of biologics—therapeutics derived from living organisms—that target various serious conditions, including age-related macular degeneration (AMD), diabetic macular edema, atopic dermatitis, asthma, and certain types of cancer. The companys focus on biologics, combined with its proprietary technology platforms, has led to the development of highly effective treatments that have significantly improved patient outcomes.
Among its flagship products, Eylea stands out as a transformative treatment for AMD, a condition that can lead to vision loss in older adults. Eylea has become a cornerstone in the management of retinal diseases. Another key product, Dupixent, is indicated for moderate-to-severe atopic dermatitis and has been a game changer for patients suffering from chronic skin conditions.
In addition to its established products, Regeneron has played a crucial role in addressing the COVID-19 pandemic. The company developed REGEN-COV, a monoclonal antibody cocktail that has demonstrated efficacy in reducing hospitalization and mortality among COVID-19 patients. This rapid response showcases Regenerons agility and commitment to public health needs, leading to regulatory approvals and widespread use across multiple regions.
Regeneron emphasizes a robust pipeline of candidates in various stages of research and clinical trials, exploring treatments for an array of diseases, including autoimmune conditions, cancers, and rare genetic disorders. The company’s extensive investment in research and development, along with strategic collaborations, furthers its mission to discover and deliver groundbreaking therapies.
In summary, Regeneron Pharmaceuticals Inc. stands as a beacon of innovation within the biotechnology landscape, dedicated to tackling serious medical issues through advanced research and leading-edge therapeutic solutions. Its continued effort to enhance patient care and its commitment to scientific excellence position it as a key player poised for sustained success in the biotech industry.
Regeneron Pharmaceuticals Inc. is a prominent biotechnology company recognized for its dedication to the discovery and development of cutting-edge therapies that address critical medical conditions. With a strong foundation in scientific research and advanced technological capabilities, Regeneron operates across several key segments that encompass a variety of therapeutic areas. Below is an extensive overview of the company’s segments, products, and services.
Segments
1. Ophthalmology
- EYLEA (aflibercept) Injection: EYLEA is a pivotal treatment in ophthalmology, functioning as a vascular endothelial growth factor (VEGF) inhibitor. It is approved for various ocular conditions, including:
- Wet Age-Related Macular Degeneration (AMD): A leading cause of vision loss in older adults.
- Diabetic Macular Edema (DME): A complication of diabetes that results in fluid accumulation in the retina.
- Macular Edema Following Retinal Vein Occlusion (RVO): A condition stemming from blockages in the retinal veins.
- Other Retinal Conditions: EYLEA’s versatile application makes it a preferred choice among healthcare providers due to its effectiveness and favorable safety profile.
2. Immunology
- Dupixent (dupilumab): This human monoclonal antibody is instrumental in treating various chronic inflammatory and allergic conditions. It is indicated for:
- Moderate-to-Severe Atopic Dermatitis: A chronic skin condition characterized by inflammation and itching.
- Chronic Rhinosinusitis with Nasal Polyposis: A condition affecting the nasal passages and sinuses, often linked to asthma.
- Eosinophilic Esophagitis: A chronic immune-mediated disease affecting the esophagus.
- Dupixent works by inhibiting IL-4 and IL-13 signaling, crucial players in the inflammatory response, thus alleviating symptoms associated with these diseases.
3. Oncology
- Regeneron is investing in advanced cancer treatments through its innovative pipeline focusing on several investigational therapies, including:
- REGN5458: An investigational anti-BCMA bispecific antibody targeting multiple myeloma, a cancer of plasma cells.
- REGN376: An anti-LAG-3 antibody under investigation for its potential to enhance anti-tumor immune responses across various malignancies.
- The oncology segment reflects Regeneron’s commitment to addressing the complex nature of cancer through innovative therapy development.
4. Neurology
- Innovating within the field of neurology, Regeneron is advancing therapies aimed at neurodegenerative diseases:
- REGN2477: An anti-amyloid beta monoclonal antibody being developed for Alzheimer’s disease targeting amyloid plaques in the brain.
- REGN2810: An anti-Tau monoclonal antibody under investigation for its potential in treating tau-related neurodegenerative disorders.
- The focus in neurology emphasizes addressing unmet needs in complex aging-related illnesses.
5. Infectious Diseases
- Regeneron has made significant contributions in the realm of infectious diseases with the evolution of novel therapies:
- REGEN-COV: An investigational monoclonal antibody cocktail designed for the treatment and prevention of COVID-19. This therapy aims to neutralize the virus and has demonstrated efficacy in preventing severe outcomes associated with the disease.
Products and Services
1. Discovery Research
- Regeneron features advanced technology platforms that underline its drug discovery process:
- VelociGene: This proprietary technology accelerates the generation of genetically engineered mouse models, facilitating the understanding of disease mechanisms and therapeutic testing.
- Regeneron Genetics Center: A collaborative initiative dedicated to sequencing and analyzing human genetic data, enabling the identification of innovative therapeutic targets informed by genetic insights.
2. Drug Development
- The company maintains a rigorous pipeline that spans various therapeutic areas, including ophthalmology, immunology, oncology, neurology, and infectious diseases. Utilizing state-of-the-art research methodologies, Regeneron integrates advanced technologies like machine learning, CRISPR, and high-throughput sequencing to improve drug development timelines and outcomes.
3. Manufacturing
- Regeneron operates a sophisticated manufacturing facility in New York, designed to produce biologic products like EYLEA and Dupixent. The facility is equipped with advanced technologies ensuring the highest standards of quality, safety, and efficacy for biologic drug production, facilitating large-scale manufacturing capabilities.
4. Commercialization
- A proficient global commercial team drives Regeneron’s marketing and sales strategies across various markets. This team focuses on fostering relationships with healthcare providers and stakeholders to enhance patient access to its transformative therapies, maintaining an emphasis on patient-centric approaches.
5. Clinical Development Services
- Beyond traditional commercialization efforts, Regeneron engages extensively in clinical development services, which encompass:
- Trial Design and Conduct: Developing and executing clinical trials to evaluate the safety and efficacy of new drugs.
- Collaborative Research Initiatives: Partnering with other biopharmaceutical entities to expand research efforts and advance innovative therapeutic solutions.
Conclusion
Regeneron Pharmaceuticals Inc. operates at the forefront of the biotechnology industry, offering an extensive range of segments, products, and services that substantially impact various therapeutic areas, including ophthalmology, immunology, oncology, neurology, and infectious diseases. By harnessing a commitment to rigorous scientific research, advanced technology, and a relentless patient-centric focus, Regeneron strives to enhance the quality of life for patients suffering from serious illnesses while fulfilling its mission of developing transformative medicines.
Segments
1. Ophthalmology
- EYLEA (aflibercept) Injection: EYLEA is a pivotal treatment in ophthalmology, functioning as a vascular endothelial growth factor (VEGF) inhibitor. It is approved for various ocular conditions, including:
- Wet Age-Related Macular Degeneration (AMD): A leading cause of vision loss in older adults.
- Diabetic Macular Edema (DME): A complication of diabetes that results in fluid accumulation in the retina.
- Macular Edema Following Retinal Vein Occlusion (RVO): A condition stemming from blockages in the retinal veins.
- Other Retinal Conditions: EYLEA’s versatile application makes it a preferred choice among healthcare providers due to its effectiveness and favorable safety profile.
2. Immunology
- Dupixent (dupilumab): This human monoclonal antibody is instrumental in treating various chronic inflammatory and allergic conditions. It is indicated for:
- Moderate-to-Severe Atopic Dermatitis: A chronic skin condition characterized by inflammation and itching.
- Chronic Rhinosinusitis with Nasal Polyposis: A condition affecting the nasal passages and sinuses, often linked to asthma.
- Eosinophilic Esophagitis: A chronic immune-mediated disease affecting the esophagus.
- Dupixent works by inhibiting IL-4 and IL-13 signaling, crucial players in the inflammatory response, thus alleviating symptoms associated with these diseases.
3. Oncology
- Regeneron is investing in advanced cancer treatments through its innovative pipeline focusing on several investigational therapies, including:
- REGN5458: An investigational anti-BCMA bispecific antibody targeting multiple myeloma, a cancer of plasma cells.
- REGN376: An anti-LAG-3 antibody under investigation for its potential to enhance anti-tumor immune responses across various malignancies.
- The oncology segment reflects Regeneron’s commitment to addressing the complex nature of cancer through innovative therapy development.
4. Neurology
- Innovating within the field of neurology, Regeneron is advancing therapies aimed at neurodegenerative diseases:
- REGN2477: An anti-amyloid beta monoclonal antibody being developed for Alzheimer’s disease targeting amyloid plaques in the brain.
- REGN2810: An anti-Tau monoclonal antibody under investigation for its potential in treating tau-related neurodegenerative disorders.
- The focus in neurology emphasizes addressing unmet needs in complex aging-related illnesses.
5. Infectious Diseases
- Regeneron has made significant contributions in the realm of infectious diseases with the evolution of novel therapies:
- REGEN-COV: An investigational monoclonal antibody cocktail designed for the treatment and prevention of COVID-19. This therapy aims to neutralize the virus and has demonstrated efficacy in preventing severe outcomes associated with the disease.
Products and Services
1. Discovery Research
- Regeneron features advanced technology platforms that underline its drug discovery process:
- VelociGene: This proprietary technology accelerates the generation of genetically engineered mouse models, facilitating the understanding of disease mechanisms and therapeutic testing.
- Regeneron Genetics Center: A collaborative initiative dedicated to sequencing and analyzing human genetic data, enabling the identification of innovative therapeutic targets informed by genetic insights.
2. Drug Development
- The company maintains a rigorous pipeline that spans various therapeutic areas, including ophthalmology, immunology, oncology, neurology, and infectious diseases. Utilizing state-of-the-art research methodologies, Regeneron integrates advanced technologies like machine learning, CRISPR, and high-throughput sequencing to improve drug development timelines and outcomes.
3. Manufacturing
- Regeneron operates a sophisticated manufacturing facility in New York, designed to produce biologic products like EYLEA and Dupixent. The facility is equipped with advanced technologies ensuring the highest standards of quality, safety, and efficacy for biologic drug production, facilitating large-scale manufacturing capabilities.
4. Commercialization
- A proficient global commercial team drives Regeneron’s marketing and sales strategies across various markets. This team focuses on fostering relationships with healthcare providers and stakeholders to enhance patient access to its transformative therapies, maintaining an emphasis on patient-centric approaches.
5. Clinical Development Services
- Beyond traditional commercialization efforts, Regeneron engages extensively in clinical development services, which encompass:
- Trial Design and Conduct: Developing and executing clinical trials to evaluate the safety and efficacy of new drugs.
- Collaborative Research Initiatives: Partnering with other biopharmaceutical entities to expand research efforts and advance innovative therapeutic solutions.
Conclusion
Regeneron Pharmaceuticals Inc. operates at the forefront of the biotechnology industry, offering an extensive range of segments, products, and services that substantially impact various therapeutic areas, including ophthalmology, immunology, oncology, neurology, and infectious diseases. By harnessing a commitment to rigorous scientific research, advanced technology, and a relentless patient-centric focus, Regeneron strives to enhance the quality of life for patients suffering from serious illnesses while fulfilling its mission of developing transformative medicines.